System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish 8 citations

PubMed: 36499368 DOI: 10.3390/ijms232315040

B4GALT1 as a New Biomarker of Idiopathic Pulmonary Fibrosis.

Int J Mol Sci 23(23)

Authors: Claudia De Vitis, Michela D'Ascanio, Andrea Sacconi, Dario Pizzirusso, Valentina Salvati, Massimiliano Mancini, Giorgia Scafetta, Roberto Cirombella, Francesca Ascenzi, Sara Bruschini, Antonella Esposito, Silvia Castelli, Claudia Salvucci, Leonardo Teodonio, Bruno Sposato, Angela Catizone, Arianna Di Napoli, Andrea Vecchione, Gennaro Ciliberto, Salvatore Sciacchitano, Alberto Ricci, Rita Mancini

Affiliations

  • Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, University of Rome "Sapienza", 00185 Rome, Italy.
  • UOC Respiratory Disease, Sant'Andrea Hospital, 00189 Rome, Italy.
  • UOSD Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Scientific Direction, IRCCS Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.
  • Morphologic and Molecular Pathology Unit, S. Andrea University Hospital, 00189 Rome, Italy.
  • Department of Experimental and Clinical Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy.
  • Division of Thoracic Surgery, Sant'Andrea Hospital, University of Rome "Sapienza", 00185 Rome, Italy.
  • Pneumology Department, Azienda USL Toscana Sud-Est, "Misericordia" Hospital, 58100 Grosseto, Italy.
  • Department of Anatomy, Histology, Forensic-Medicine and Orthopedics, Sapienza University of Rome, 00161 Rome, Italy.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a disease characterized by progressive scarring of the lung that involves the pulmonary interstitium. The disease may rapidly progress, leading to respiratory failure, and the long-term survival is poor. There are no accurate biomarkers available so far. Our aim was to evaluate the expression of the B4GALT1 in patients with IPF. Analysis of B4GALT1 gene expression was performed in silico on two gene sets, retrieved from the Gene Expression Omnibus database. Expression of B4GALT1 was then evaluated, both at the mRNA and protein levels, on lung specimens obtained from lung biopsies of 4 IPF patients, on one IPF-derived human primary cell and on 11 cases of IPF associated with cancer. In silico re-analysis demonstrated that the B4GALT1 gene was overexpressed in patients and human cell cultures with IPF ( = 0.03). Network analysis demonstrated that B4GALT1 upregulation was correlated with genes belonging to the EMT pathway ( = 0.01). The overexpression of B4GALT1 was observed, both at mRNA and protein levels, in lung biopsies of our four IPF patients and in the IPF-derived human primary cell, in other fibrotic non-lung tissues, and in IPF associated with cancer. In conclusion, our results indicate that B4GALT1 is overexpressed in IPF and could represent a novel marker of this disease.

MeSH

Biomarkers, Cells, Lung Neoplasms, Immunohistochemistry, Biopsy, Genes, Idiopathic Pulmonary Fibrosis

Cited by